表紙
市場調查報告書
商品編碼
1077279

肺水腫治療藥的全球市場 - 2022年∼2029年

Global Pulmonary Edema Therapeutics Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球肺水腫治療藥市場相關調查,提供市場概要,以及各類藥物,各類型,各給藥途徑,各流通管道,各地區趨勢,競爭情形,及加入此市場的主要企業簡介等資訊。

目錄

第1章 調查手法和範圍

第2章 市場定義和概要

第3章 摘要整理

  • 各類藥物,市場明細
  • 各類型,市場明細
  • 各給藥途徑,市場明細
  • 各流通管道,市場明細
  • 各地區,市場明細

第4章 市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 產業分析

  • 供應鏈分析
  • 價格分析
  • 未滿足需求

第6章 COVID-19分析

第7章 各類藥物

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%)、各類藥物
    • 市場魅力指數,各類藥物
  • 利尿劑
    • Furosemide(樂洩錠)(Lasix)
    • 其他
    • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2021年∼2029年)
  • 類鴉片物質止痛藥
  • 血管擴張藥
  • 降壓藥
  • 事變力藥
  • 其他

第8章 各類型

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%)、各類型
    • 市場魅力指數,各類型
  • 心原性肺水腫
    • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2021年∼2029年)
  • 非心平原性肺水腫

第9章 各給藥途徑

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%)、各給藥途徑
    • 市場魅力指數,各給藥途徑
  • 口服
    • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2021年∼2029年)
  • 靜脈內

第10章 各流通管道

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%)、各流通管道
    • 市場魅力指數,各流通管道
  • 院內藥局
    • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2021年∼2029年)
  • 零售藥局
  • 線上藥局
  • 其他

第11章 各地區

  • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2021年∼2029年),各地區
    • 市場魅力指數,各地區
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東·非洲

第12章 競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準
  • 值得注意的主要企業的清單

第13章 企業簡介

  • Pfizer Inc.
  • sanofi-aventis U.S. LLC
  • Purdue Phanna L.P.
  • Evus Pharmaceuticals, LLC
  • NovaDel Pharma Inc.
  • American Regent, Inc.
  • Medicure Inc.
  • Copperhead Chemical Company

第14章 全球肺水腫治療藥市場-DataM

目錄
Product Code: DMPH5049

Market Overview

The global pulmonary edema therapeutics market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Pulmonary edema is a disorder that occurs when there is too much fluid in the lungs. This fluid gathers in the lungs' many air sacs, making breathing harder. Cardiac issues usually cause pulmonary edema. Pulmonary edema can be acute, appears suddenly, or chronic. It develops over time. If the patient is treated quickly, the prognosis improves. Supplemental oxygen and medicines are commonly used to treat pulmonary edema, depending on the reason.

Market Dynamics

Increasing biomarkers to diagnose Pulmonary Edema is expected to drive market growth.

Biomarkers to diagnose pulmonary edema are becoming more common in recent diagnostic evaluations. A biomarker is a detectable sign of a particular biological state or situation, like a disease process. Clinical examination and imaging testing are the most prevalent procedures for diagnosing pulmonary edema. Blood tests are also useful for detecting disease by looking for biomarkers in the blood. Biomarkers are less expensive than other types of evaluation tests.

Also, these devices can identify other cardiac or kidney disorders. Moreover, the high prevalence of cardiovascular diseases such as carotid artery disease, cardiomyopathy, heart valve problems, and hypertension has increased the demand for therapeutics. Thus, the market is expected to drive in the forecast period.

Restraint:

Side effects caused by the drugs and availability of substitutes are factors the market is expected to hamper the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The primary cause of COVID-19 mortality is aberrant alveolar fluid metabolism in the lungs, which results in fluid buildup in the alveolar airspace. This illness is known as pulmonary edema and is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In severe Coronavirus Disease (COVID-19) individuals, numerous potential processes cause pulmonary edema, and identifying those pathways may help with the care of this condition. The aberrant lung humoral metabolism has received little consideration among the current COVID-19 treatment options. Surprisingly, good lung humoral metabolism balance may reduce COVID-19 deaths, limiting the potential of healthcare facilities lacking the capacity to deliver ventilator-assisted respiration. In contrast, the pandemic is interrupting the supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the COVID-19 pandemic has affected the market.

Segment Analysis

Cardiogenic pulmonary edema segment is expected to hold the largest market share in pulmonary edema therapeutics market

The cardiogenic pulmonary edema segment is expected to dominate in 2020. The segment benefits because it is most common, and increased pressures in the heart cause it. It's usually a result of heart failure. When a diseased or overworked left ventricle can't pump out enough of the blood it gets from your lungs, pressures in the heart go up. The increased pressure pushes fluid through the blood vessel walls into the air sacs. The medical conditions that can cause heart failure and lead to pulmonary edema include Coronary artery disease, Cardiomyopathy, Heart valve problems, High blood pressure (hypertension), and other heart problems cause it. Therefore, it has increased the demand for the treatment, due to which the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global pulmonary edema therapeutics market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of pulmonary edema, rising geriatric population, well-established infrastructure, rising health care investments and rising affordability of drugs, product launches and collaborations by the key market players in the region are some of the factors the market is expected to boost in the forecast period. For instance, Pulmonary edema commonly affects individuals older than 65 years of age. Males are more commonly affected by pulmonary edema than a woman. More than a million Americans are diagnosed with pulmonary edema each year, yet many people don't know the condition or whether they're at risk. Moreover, On May 8, 2020, Amgen Inc. and Cytokinetics Inc. announced that the US Food and Drug Administration (FDA) had granted omecamtiv mecarbil, a novel selective cardiac myosin activator, also known as cardiac myotrope, Fast Track designation for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the pulmonary edema therapeutics market are Pfizer Inc., sanofi-aventis U.S. LLC, Purdue Phanna L.P., Evus Pharmaceuticals, LLC , NovaDel Pharma Inc., American Regent, Inc., Medicure Inc. and Copperhead Chemical Company.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company. The company develops and produces medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. Its medicines and vaccines provide value for healthcare providers and patients through the treatment of diseases improvements in health wellness. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.

­Product Portfolio:

FUROSEMIDE (furosemide): Furosemide belongs to a group of medicines called loop diuretics (also known as water pills). It is given to help treat fluid retention (edema) and swelling caused by congestive heart failure, liver disease, kidney disease, or other medical conditions.

Why Purchase the Report?

Visualize the composition of the pulmonary edema therapeutics market segmentation by drug class, type, route of administration, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in pulmonary edema therapeutics market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of pulmonary edema therapeutics market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global pulmonary edema therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market Snippet by Type
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Distribution channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing biomarkers to diagnose Pulmonary Edema is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects caused by the drugs and availability of substitutes are factors the market is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class Segment
  • 7.2. Diuretics*
    • 7.2.1. Furosemide (Lasix)
    • 7.2.2. Others
    • 7.2.3. Introduction
    • 7.2.4. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Opioid Analgesics
    • 7.3.1. Morphine IV
    • 7.3.2. Others
  • 7.4. Vasodilators
  • 7.5. Antihypertensives
    • 7.5.1. Nitroglycerin (Nitromist, Nitrostat, others)
    • 7.5.2. Nitroprusside (Nitropress)
    • 7.5.3. Others
  • 7.6. Inotropes
  • 7.7. Others

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type Segment
  • 8.2. Cardiogenic Pulmonary Edema*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Non-cardiogenic Pulmonary Edema

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Intravenous

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Pfizer Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. sanofi-aventis U.S. LLC
  • 13.3. Purdue Phanna L.P.
  • 13.4. Evus Pharmaceuticals, LLC
  • 13.5. NovaDel Pharma Inc.
  • 13.6. American Regent, Inc.
  • 13.7. Medicure Inc.
  • 13.8. Copperhead Chemical Company

LIST NOT EXHAUSTIVE

14. Global Pulmonary Edema Therapeutics Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us